Based on these data, a randomized, double-blind, phase III trial (ROBUST, NCT02285062) comparing lenalidomide plus R-CHOP versus placebo plus R-CHOP in newly diagnosed ABC-subtype DLBCL defined by central GEP assay (Lymph2Cx) is open and is actively recruiting. Here, DDIT3 is linked to diffuse large B-cell lymphoma.